期刊
JOURNAL OF ALZHEIMERS DISEASE
卷 51, 期 1, 页码 227-236出版社
IOS PRESS
DOI: 10.3233/JAD-150824
关键词
Alzheimer's disease; Alzheimer's disease neuroimaging Initiative; diagnostic markers; international working group-2 criteria; progression markers
资金
- ADNI (National Institutes of Health) [U01 AG024904]
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- BioClinica, Inc
- Biogen Idec Inc
- Bristol-Myers Squibb Co
- F. Hoffmann-LaRoche Ltd
- Genetech, Inc
- GE Healthcare
- Innogenetics, NV
- IXICO Ltd
- Janssen Alzheimer Immunotherapy Research & Development LLC
- Medpace, Inc
- Merck Co, Inc
- Meso Scale Diagnostics, LLC
- NeuroRx Research
- Novartis Pharmaceuticals, Co
- Pfizer, Inc
- Piramal Imaging
- Servier
- Synarc Inc
- Takeda Pharmaceutical Co.
- Canadian Institutes of Health Research
- National Natural Science Foundation of China [81171209, 81371406, 81471309]
Background: The International Working Group (IWG) recently proposed the revised diagnostic criteria for Alzheimer's disease (AD) to define and refine several types of AD, and to reclassify AD-related biomarkers into diagnostic and progression markers, but its performance is not known. Objective: This study was designed to describe the application of the revised IWG criteria in the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset, and to ascertain whether diagnostic and progression markers show significant differences in their relationships to AD severity and progression. Methods: Based on the requirements of the refined criteria, 857 ADNI subjects with memory evaluation and at least one pathophysiological marker (CSF or amyloid imaging biomarkers) were eligible and reclassified in this study, and we calculated the associations of diagnostic (CSF and amyloid PET) and progression markers (MRI and fluorodeoxyglucose-PET) with AD severity and progression respectively. Results: The majority (84.2%) of ADNI AD group (n = 117) and 173 MCI (37.4%) subjects in ADNI met the definition of typical AD; and 105 cognitively normal (41.0%) individuals were diagnosed as asymptomatic AD. Furthermore, diagnostic and progression markers showed significant differences when correlated to AD severity and progression. Conclusion: A large proportion of AD dementia subjects were categorized as typical AD, and the revised criteria could identify typical AD from MCI status as well as asymptomatic AD at the asymptomatic stage. Moreover, the significant differences between diagnostic and progression markers further supported the new biomarkers categorization in the refined criteria.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据